Merck's new Keytruda flat dose could add $1B each year to U.S. healthcare spending

17th July 2017 Uncategorised 0

Merck & Co.’s move to introduce Keytruda as a flat-dose med in non-small cell lung cancer comes with big costs, health experts say, but the company says it’ll prevent waste and make reimbursement easier.

More: Merck's new Keytruda flat dose could add B each year to U.S. healthcare spending
Source: fierce